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Abstract
Dose-response models are applied to animal-based cancer risk assessments and human-
based clinical trials usually with small samples. For sparse data, we rely on a parametric
model for efficiency, but posterior inference can be sensitive to an assumed model. In
addition, when we utilize prior information, multiple experts may have different prior
knowledge about the parameter of interest. When we make sequential decisions to
allocate experimental units in an experiment, an outcome may depend on decision rules,
and each decision rule has its own perspective. In this chapter, we address the three
practical issues in small-sample dose-response studies: (i) model-sensitivity, (ii) disagree-
ment in prior knowledge and (iii) conflicting perspective in decision rules.
Keywords: dose-response models, model-sensitivity, model-averaging, prior-sensitivity,
consensus prior, Bayesian decision theory, individual-level ethics, population-level
ethics, Bayesian adaptive designs, sequential decisions, continual reassessment method,
c-optimal design, Phase I clinical trials
1. Introduction
Dose-response modeling is often used to learn about the effect of an agent on a particular
outcome with respect to dose. It is widely applied to animal-based cancer risk assessments and
human-based clinical trials. A sample size is typically small; so many statistical issues can arise
from a limited amount of data. The issues include the impact of a misspecified model, prior-
sensitivity, and conflicting ethical perspectives in clinical trials. In this chapter, we focus on
cases when an outcome variable of interest is binary (a predefined event happened or not)
when an experimental unit is exposed to a dose. Main ideas are preserved for cases when an
outcome variable is continuous or discrete.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
There are two different approaches to statistical inference. One approach is called frequentist
inference. In this framework, we often rely on the sampling distribution of a statistic and large-
sample theories. Another approach is called Bayesian inference. It is founded on Bayes’ Theo-
rem, and it allows researchers to express prior knowledge independent of data. In a small-
sample study, Bayesian inference can be more useful than frequentist inference because we can
incorporate both researcher’s prior knowledge and observed data to make inference for the
parameter of interest. Bayesian ideas are briefly introduced for dose-response modeling with a
binary outcome in Section 2.
In a small-sample study, we often rely on a parametric model to gain statistical efficiency
(i.e., less variance in parameter estimation), but our inference can be severely biased by the
use of a wrong model. To account for model uncertainty, it is reasonable to specify multiple
models and make inference based on “averaged-inference.” In this regard, Bayesian model
averaging (BMA) is a useful method to gain robustness [1]. The BMA method has a wide
range of application, and we focus its application to animal-based cancer risk assessments in
Section 3.
In clinical trials, study participants are real patients, and therefore, we need to carefully
consider ethics. There are conflicting perspectives of individual- and population-level ethics
in early phase clinical trials. Individual-level ethics focuses on the benefit of trial partici-
pants, whereas population-level focuses on the benefit of future patients, which may require
some level of sacrifice from trial participants. We compare the two conflicting perspectives in
clinical trials based on Bayesian decision theory, and we discuss a compromising method in
Section 4 [2, 3].
A sample size for an early phase (Phase I) clinical trial is often less than 30 subjects. Dose
allocations for first few patients and statistical inference for future patients heavily depend on
researcher’s prior knowledge in sparse data. When multiple researchers have different prior
knowledge about a parameter of interest, one compromising approach is to combine their
prior elicitations and average them (i.e., consensus prior) [4, 5]. When we average the prior
elicitations, there are two different approaches to determine the weight of each prior elicita-
tion, weights determined before observing data and after observing data. We discuss operating
characteristics of the two different weighting methods in the context of Phase I clinical trials
in Section 5.
2. Bayesian inference
In statistics, we address a research question by a parameter, which is often denoted by θ. We
begin Bayesian inference by modeling the prior knowledge about θ. A function, which
models the prior knowledge about θ, is called the prior density function of θ, and we denote
it by f(θ). It is a non-negative function, which satisfies
ð
Ω
f ðθÞ dθ ¼ 1, whereΩ is the set of all
possible values of θ (i.e., parameter space). We then model data y
!
¼ ðy1,…, ynÞ given θ. The
likelihood function, denoted by f ðy
!
jθÞ, quantifies the likelihood of observing a particular
Bayesian Inference168
sample y
!
¼ ðy1,…, ynÞ under an assumed probability model. By Bayes’ Theorem, we update
our knowledge about θ after observing data y
!
as
f ðθjy
! Þ ¼
f ðy
!
jθÞ f ðθÞ
f ðy
!
Þ
: ð1Þ
The function f ðθjy
!
Þ is called the posterior density function of θ given data y
!
. Since we treat
observed data y
!
¼ ðy1,…, ynÞ as fixed numbers, we often express Eq. (1) as follows
f ðθjy
! Þ ∝ f ðy
!
jθÞ f ðθÞ ¼ k f ðy
!
jθÞ f ðθÞ , ð2Þ
where k is the normalizing constant which makes
ð
Ω
f ðθjy
!
Þ dθ ¼ 1. We can often realize f ðθjy
!
Þ
based on the prior density function f(θ) and the likelihood function f ðy
!
jθÞwithout considering
the denominator f ðy
!
Þ ¼
ð
f ðyjθÞ f ðθÞ dθ in Eq. (1) which is called the marginal likelihood.
2.1. Example
Suppose we observe n = 20 rats for 2 years. Let pi be the parameter of interest, which is
interpreted as the probability of developing some type of tumor. Suppose a researcher models
the prior knowledge about pi using the prior density function
f ðpiÞ ¼
Γðaþ bÞ
ΓðaÞ ΓðbÞ
pi
a1 ð1 piÞb1 , 0 < pi < 1 : ð3Þ
It is known as the beta distribution with shape parameters a > 0 and b > 0. We often denote the
beta distribution by pi  Betaða, bÞ, and the values of a and bmust be specified by the researcher
independent from data. Let y
!
¼ ðy1,…, ynÞ denote observed data, where yi = 1 if the i
th rat
developed tumor and yi = 0 otherwise. Assuming y1,…, yn are independent observations, the
likelihood function is as follows
f ðy
! jpiÞ ¼
Yn
i¼1
pi
yi ð1 piÞ1yi ¼ pis ð1 piÞns , ð4Þ
where s ¼
Xn
i¼1
yi is the total number of rats developed tumor. By Eq. (2), the posterior
density function of pi is as follows
f ðpijy
! Þ ¼ kpiaþs1 ð1 piÞbþns1 , ð5Þ
where k ¼ ΓðaþbþnÞ
ΓðaþsÞΓðbþnsÞ is the normalizing constant, which makes
ð1
0
f ðpijy
!
Þ dpi ¼ 1. We can
recognize that pijy
!
 Betaðaþ s, bþ n sÞ.
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If the researcher fixed a = 2 and b =3 and observed s = 9 from a sample of size n = 20, the prior
density function is f ðpiÞ ¼ kpi ð1 piÞ2 with k ¼ Γð5Þ
Γð2ÞΓð3Þ ¼ 12, and the posterior density function
is f ðpijy
!
Þ ¼ kpi10 ð1 piÞ13 with k ¼ Γð25Þ
Γð11ÞΓð14Þ ¼ 27457584. The prior and posterior distributions
are shown in Figure 1. The knowledge about pi becomes more certain (less variance) after
observing the data.
2.2. Example
This example is simplified from Shao and Small [6]. In dose-response studies, we model pi as a
function of dose x. There are many link functions between pi and x used in practice. In this
example, we focus on a link function
pix ¼
eβ0þβ1x
1þ eβ0þβ1x
ð6Þ
which is known as a logistic regression model. It is commonly assumed that a dose-response
curve increases with respect to dose, so we assume β1 > 0 (and β0 can be any real number).
There are two regression parameters in Eq. (6), β0 and β1, and we denote them as β
!
¼ ðβ0, β1Þ.
Figure 2 presents two dose-response curves. The solid curve is generated by β
!
¼ ð1; 2Þ, and
the dotted curve is generated by β
!
¼ ð2; 5Þ. As β0 increases, the background risk pi0 ¼ e
β0
1þeβ0
increases, where pi0 is interpreted as the probability of tumor development at dose x = 0. The
dose-response curve increases when β1 > 0, and it decreases when β1 < 0. The rate of change in
the dose-response curve is determined by|β1|.
To express prior knowledge about β
!
, we need to find an appropriate prior density function f ðβ
!
Þ.
It is not simple because it is difficult to express one’s knowledge on the two-dimensional
parameters β
!
¼ ðβ0, β1Þ. For mathematical convenience, some practitioners use a flat prior den-
sity function f ðβ
!
Þ∝ 1. Another way of expressing a lack of prior knowledge about β
!
is as follows
f ðβ
!
Þ ∝
1
2piσ2
e
β2
0
þβ2
1
2σ2 Iβ1>0 ð7Þ
with an arbitrarily large value of σ [6]. When a reliable source of prior information is available,
there is a practical method, which is known as the conditional mean prior [7], and it will be
discussed in a later section (see Section 4.2). In an experiment, the experimental doses
x
!
¼ ðx1,…, xnÞ are fixed, and we observe random binary outcomes y
!
¼ ðy1,…, ynÞ. Given y
!
(and fixed x
!
), the likelihood function is as follows
f ðy
! jβ
!
Þ ¼
Yn
i¼1
eβ0þβ1xi
1þ eβ0þβ1xi
 yi 1
1þ eβ0þβ1xi
 1yi
¼
eβ0s1þβ1s2Yn
i¼1
ð1þ eβ0þβ1xiÞ
, ð8Þ
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where s1 ¼
Xn
i¼1
yi and s2 ¼
Xn
i¼1
xiyi. By incorporating both prior and data, the posterior
density function is as follows
f ðβ
!
jy
!
Þ ∝ f ðβ
!
Þ
eβ0s1þβ1s2Yn
i¼1
1þ eβ0þβ1xi
  : ð9Þ
In an animal-based studies, one parameter of interest is the median effective dose, which is
denoted by ED50. It is the dose, which satisfies
piED50 ¼
eβ0þβ1ED50
1þ eβ0þβ1ED50
¼ :5 , ð10Þ
and it can be shown that ED50 ¼ 
β0
β1
by algebra. In the case of β0 = 2 and β1 = 5, we have
ED50 = .4 as describe in the figure with the dotted curve. In the case of β0 = 1 and β2 = 2, we
have ED50 = .5 as described in the figure with the solid curve.
In 1997, International Agency for Research on Cancer classified 2,3,7,8-Tetrachlorodibenzo-p-
dioxin (known as TCDD) as a carcinogen for humans based on various empirical evidence [8].
Prior and Posterior Distributions
θ
D
e
n
s
it
y
0.0 0.2 0.4 0.6 0.8 1.0
0
1
2
3
4
5
6
Prior
Posterior
Figure 1. The prior f(pi) in the dotted curve and the posterior f ðpijy
!
Þ in the solid curve.
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In 1978, Kociba et al. presented the data on male Sprague-Dawley rats at four experimental
doses 0, 1, 10 and 100 nanograms per kilogram per day (ng/kg/day) [9]. In the control dose
group, nine of 86 rats developed tumor (known as hepatocellular carcinoma); three of 50 rats
developed the tumor at dose 1; 18 of 50 rats developed the tumor at dose 10; and 34 of 48 rats
developed the tumor at dose 100 [6]. Without loss of generosity, we let xi = 0 for i = 1,…, 86; xi =
1 for i = 87,…136; xi = 10 for i = 137,…, 186; and xi = 100 for i = 187,…, 234. The given
information is sufficient to calculate s1 ¼
Xn
i¼1
yi ¼ 64 and s2 ¼
Xn
i¼1
xiyi ¼ 3583. By the use
of the flat prior f ðβ
!
Þ ∝ 1 with the restriction β1 > 0, given the observed sample of size n = 234,
we can generate random numbers of β
!
¼ ðβ0, β1Þ from the posterior density function
f ðβ
!
jy
!
Þ ∝
eβ0s1þβ1s2Yn
i¼1
ð1þ eβ0þβ1xiÞ
Iβ1>0 , ð11Þ
where Iβ1>0 ¼ 1 if β1 > 0 and Iβ1>0 ¼ 0 otherwise. Using a method of Markov Chain Monte
Carlo (MCMC), we can approximate the posterior distribution of β
!
as shown in the left panel
of Figure 3. By transforming (β0, β1) to ED50 ¼ 
β0
β1
, we can approximate the posterior
Dose−Response Curves (Logistic Link)
x
pi
0.0 0.2 0.4 0.6 0.8 1.0
0
.0
0
.2
0
.4
0
.6
0
.8
1
.0
Figure 2. Two dose-response curves using the logistic link.
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distribution of the median effective dose ED50 as shown in the right panel. The posterior mean
of ED50 is EðED50jy
!
Þ ¼ 64:9 with 95% credible interval (50.8, 82.5), the 2.5th percentile and the
97.5th percentile of the posterior distribution.
3. Bayesian model averaging
In a small sample, we borrow the strength of a parametric model to gain efficiency in param-
eter estimation. However, an assumed model may not describe the true dose-response rela-
tionship adequately. The impact of model misspecification is not negligible particularly in a
poor experimental design. In such a limited practical situation, Bayesian model averaging
(BMA) can be a useful method to account for model uncertainty. It is widely applied in
practice, and in this section, we focus on the application to cancer risk assessment for the
estimation of a benchmark dose [1, 6, 10, 11].
Let θ denote a parameter of interest. Suppose we have a set of K candidate models denoted by
M ¼ fM1,…,MKg. Let β
!
k denote the vector of regression parameters under modelMk for k =1,
…, K. Suppose θ is a function of β
!
k, and the interpretation of θ must be common across all
models. Let f ðβ
!
kjMkÞ and f ðy
!
jβ
!
k,MkÞ denote the prior density function and the likelihood
function, respectively, underMk. By the Law of Total Probability, the posterior density function
of θ is as follows
f ðθjy
! Þ ¼
XK
k¼1
f ðθjMk, y
!
Þ PðMkjy
!
Þ : ð12Þ
In Eq. (12), the posterior density function f ðθjMk, y
!
Þ depends on model Mk, and the posterior
model probability PðMkjy
!
Þ quantifies the plausibility of modelMk after observing data, which
is given by
Regression Parameters
β0
β 1
−3.0 −2.5 −2.0 −1.5 −1.0
0
.0
0
0
.0
2
0
.0
4
Median Effective Dose
ED50
0 20 40 60 80 100
Figure 3. Approximate posterior distributions of (β0, β1) and ED50 ¼ 
β0
β1
.
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PðMkjy
! Þ ¼
f ðy
!
jMkÞPðMkÞXK
j¼1
f ðy
!
jMjÞ PðMjÞ
: ð13Þ
In Eq. (13), the prior model probability P(Mk) is determined before observing data such that
PðMkÞ > 0 for k ¼ 1;…, K and
XK
k¼1
PðMkÞ ¼ 1. The marginal likelihood underMk requires the
integration
f ðy
! jMkÞ ¼
ð
f ðy
!
jβ
!
k,MkÞ f ðβ
!
kjMkÞ dβ
!
k : ð14Þ
In the BMA method, all K models contribute to inference of θ through the averaged posterior
density function in Eq. (12), and the weight of contribution is determined by Bayes’ Theorem
in Eq. (13).
3.1. Example
This example is continued from the example in Section 2.2. Recall pix is interpreted as the
probability of a toxic event (tumor development) at dose x. In many cancer risk assessments,
a parameter of interest is θγ at a fixed risk level γ, which is defined as follows
γ ¼
piθγ  pi0
1 pi0
ð15Þ
or equivalently piθγ ¼ pi0 þ ð1 pi0Þγ. In words, θγ is a dose corresponding to a fixed increase
in the risk level. In frequentist framework, Crump defined a benchmark dose as a lower
confidence limit for θγ [12]. In Bayesian framework, an analogous definition would be a lower
credible bound (i.e., a fixed low percentile of the posterior distribution of θγ). The definition is
widely applied to the public health protection [13].
In practice, γ is fixed between 0.01 and 0.1. Often, the estimation of θγ is highly sensitive to an
assumed dose-response model because we have a lack of information at low doses. Shao and
Small fixed γ = 0.1 and applied BMA with K = 2 models, logistic model and quantal-linear
model [6]. In the quantal-linear model, the probability of tumor development is modeled by
pix ¼ β0 þ ð1 β0Þð1 e
β1xÞ : ð16Þ
with the restrictions 0 < β0 < 1 and β1 > 0 under the monotonic assumption. The logistic model
was given in Eq. (6) of Section 2.2.
Let M1 denote the logistic model, and let M2 denote the quantal-linear model. Assume the
uniform prior model probabilities PðM1Þ ¼ PðM2Þ ¼ :5 and flat priors on the regression
parameters. By posterior sampling, we can approximate the posterior model probabilities
PðM1jy
!
Þ ¼ :049 and PðM2jy
!
Þ ¼ :951. Under M1, the posterior mean of θ0.1 is 20.95 with the
5th percentile 16.74. Under M2, the posterior mean is 8.25 with the 5th percentile 5.95. These
Bayesian Inference174
results are very similar to the results reported by Shao and Small [6]. From these model-
specific statistics, we can calculate the model-averaged posterior mean
Eðθ0:1jy
! Þ ¼
X2
k¼1
Eðθ0:1jMk, y
!
Þ PðMkjy
!
Þ ¼ 20:95 ð:049Þ þ 8:25 ð:951Þ ¼ 8:87 : ð17Þ
However, we are not able to calculate the 5th percentile of the model-averaged posterior
distribution based on the given statistics. In fact, we need to approximate the posterior distri-
bution f ðθ0:1jy
!
Þ, which is a mixture of f ðθ0:1jM1, y
!
Þ and f ðθ0:1jM2, y
!
Þ weighted by
PðM1jy
!
Þ ¼ :049 and PðM2jy
!
Þ ¼ :951, respectively, as shown in Figure 4. In the figure, the left
panel shows an approximation of f ðθ0:1jM1, y
!
Þ, the middle panel shows an approximation of
f ðθ0:1jM2, y
!
Þ, and the right panel shows an approximation of the averaged posterior f ðθ0:1jy
!
Þ.
The averaged posterior density f ðθ0:1jy
!
Þ is bimodal, but it is very close to f ðθ0:1jM2, y
!
Þ because
the quantal-linear modelM2 fits the data better than the logistic modelM1 by a Bayes factor of
PðM2jy
!
Þ
PðM1jy
!
Þ
¼ :951
:049 ¼ 19:4. The 5th percentile of the model-averaged posterior distribution is approx-
imately 5.97, and it is a BMA-BMD based on the BMA method proposed by Raftery et al. [1]
and the BMD estimation method suggested by Crump [12].
4. Application of Bayesian decision theory to Phase I trials
In a Phase I cancer trial, the main objectives are to study the safety of a new chemotherapy
and to determine an appropriate dose for future patients. Since trial participants are cancer
patients, dose allocations require ethical considerations. Whitehead and Williams discussed
several Bayesian approaches to dose allocations [14]. One decision rule is devised from the
perspective of trial participants (individual-level ethics), and another decision rule is devised
from the perspective of future patients (population-level ethics). However, a decision rule,
which is devised from the population-level ethics, is not widely accepted in current prac-
tice [15]. Instead, there are some proposed decision rules, which compromise between the
individual- and population-level perspectives [3, 16]. In this section, we discuss the two
Logistic Model
θ0.1
0 10 20 30 40 50
Quantal−Linear Model
θ0.1
0 10 20 30 40 50
Bayesian Model Averaging
θ0.1
0 10 20 30 40 50
Figure 4. Posterior distributions of θ0.1 from the logistic model (left panel), the quantal-linear model (middle panel), and
the Bayesian model averaging (right panel).
Bayesian Model Averaging and Compromising in Dose-Response Studies
http://dx.doi.org/10.5772/intechopen.68786
175
conflicting perspectives in Phase I clinical trials and a compromising method based on
Bayesian decision theory.
Assume a dose-response relationship follows a logistic model
pix ¼
eβ0þβ1x
1þ eβ0þβ1x
, ð18Þ
where x is a dose in the logarithmic scale (base e) and pix is the probability of observing an
adverse event due to the toxicity of a new chemotherapy at dose x. The logarithmic transforma-
tion on the dose is to satisfy pix! 0 as x ! 0. Let x
!
n ¼ ðx1,…, xnÞ denote a series of decisions for
n patients (i.e., allocated doses) and y
!
n ¼ ðy1,…, ynÞ denote a series of observed responses,
where yi = 1 indicates an adverse event and yi = 0 otherwise. Let Lðβ
!
, xnþ1Þ denote a loss by
allocating the next patient at xn+1. Based on Bayesian Decision Theory, we want to find xn+1which
minimizes the posterior mean of Lðβ
!
, xnþ1Þ. If we let A denote an action space, a set of all
possible dose allocations for the next patients, the decision rule can be written as follows:
xnþ1 ¼ argminxnþ1 ∈A E

Lðβ
!
, xnþ1Þ j y
!
n

: ð19Þ
A choice of L has a substantial impact on the operating characteristics of a Phase I trial including
(i) the degree of under- and over-dosing in trial, (ii) the observed number of adverse events at the
end of a trial, and (iii) the quality of estimation at the end of a trial.
4.1. Parameter of interest: maximum tolerable dose
Let N denote an available sample size for a Phase I clinical trial. A typical sample size is N ≤ 30.
Let γ denote a target risk level, the probability of an adverse event. In a cancer study, a typical
target risk level γ is fixed between .15 and .35 depending on the severity of an adverse event.
Then, the dose corresponding to γ is called a maximum tolerable dose (MTD) at level γ, and
we denote it by θγ in the logarithmic scale. Under the logistic model in Eq. (18), it is defined as
follows
θγ ¼
log
γ
1 γ
 
 β0
β1
:
ð20Þ
At the end of a trial (observing N responses), we estimate θγ by the posterior mean
θ^γ,N ¼ Eðθγjy
!
NÞ for future patients.
4.2. Prior density function: conditional mean priors
A consequence of sequential decisions heavily depends on a prior density function f ðβ
!
Þ. In
particular, the first decision x1 must be made based on prior knowledge only because empirical
evidence is not observed yet. In addition, the later decisions x2, x3,… and the final inference of
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θγ are substantially affected by f ðβ
!
Þ as a Phase I study is typically based on a small sample. In
this regard, we want to carefully utilize researchers’ prior knowledge about β
!
, but it may be
difficult to express their prior knowledge directly through f ðβ
!
Þ. In this section, we discuss a
method of eliciting prior knowledge, which is more tractable than prior elicitation directly on β
!
.
Suppose a researcher selects two arbitrarily doses, say x1 < x0. Then, the researcher may
express their prior knowledge by two independent beta distributions
pixi ¼
eβ0þβ1xi
1þ eβ0þβ1xi
 Betaðai, biÞ , j ¼ 1; 0: ð21Þ
Using the Jacobian transformation from ðpix1 ,pix0Þ to β
!
¼ ðβ0, β1Þ, it can be shown that the
prior density function of β
!
is given by
f ðβ
!
Þ ∝ ðx0  x1Þ
Y0
i¼1
eβ0þβ1xi
1þ eβ0þβ1xi
 ai 1
1þ eβ0þβ1xi
 bi
: ð22Þ
It is known as conditional mean priors under the logistic model [7].
4.3. Posterior density function: conjugacy
For notational convenience, we let yi = ai and ni = ai + bi for i = 1,0. By conjugacy, the posterior
density function of β
!
can be concisely written as follows
f ðβ
!
jy
!
nÞ ∝
eβ0s1þβ1s2Yn
i¼1
ð1þ eβ0þβ1xiÞ
, ð23Þ
where s1 ¼
Xn
i¼1
yi and s2 ¼
Xn
i¼1
xi yi. After observing n responses, the decision rule for
the next patient is as follows
xnþ1 ¼ argminxnþ1 ∈A
ð
Lðβ
!
, xnþ1Þ f ðβ
!
jy
!
nÞ dβ
!
: ð24Þ
4.4. Loss functions for individual- and population-level ethics
A loss function, which reflects the perspective of individual-level ethics, is as follows:
LIðβ
!
, xnþ1Þ ¼ ðxnþ1  θγÞ
2
: ð25Þ
This loss function is analogous to the original continual reassessment method proposed by
O’Quigley et al. [17]. The square error loss attempts to treat a trial participant at θγ, and the
expected square error loss is minimized by the posterior mean of θγ.
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From the perspective of population-level ethics, Whitehead and Brunier proposed a loss
function, which is equal to the asymptotic variance of the maximum likelihood estimator for
θγ [18]. The Fisher expected information matrix with a sample of size n + 1 is given by
Iðβ
!
Þ ¼
Xnþ1
i¼1
τi
Xnþ1
i¼1
τixiXnþ1
i¼1
τixi
Xnþ1
i¼1
τix
2
i
0
@
1
A, ð26Þ
where τi ¼ πxið1 πxiÞ. Then, the loss function (the asymptotic variance) is given by
LPðβ
!
, xnþ1Þ ¼ ∇h
!
ðβ
!
Þ
h iT
Iðβ
!
Þ
h i1
∇h
!
ðβ
!
Þ
h i
, ð27Þ
where
∇h
!
ðβ
!
Þ ¼
∂θγ
∂β0
∂θγ
∂β1
0
BB@
1
CCA ¼  1β1
1
θγ
 
ð28Þ
is the gradient vector, the partial derivatives of θγ with respect to β0 and β1. Kim and Gillen
decomposed the population-level loss function as follows
LPðβ
!
, xnþ1Þ ¼
τnþ1ðxnþ1  θγÞ
2 þ s
ð0Þ
n ðθγ  μnÞ
2 þ σ2n
h i
s
ð0Þ
n s
ð2Þ
n  s
ð1Þ
n s
ð1Þ
n
h i
þ s
ð0Þ
n τnþ1 ðxnþ1  μnÞ
2 þ σ2n
h i , ð29Þ
where
s
ðmÞ
n ¼
Xn
i¼1
τix
m
i , m ¼ 0; 1; 2,
μn ¼
Xn
i¼1
wixi,
σ2n ¼
Xn
i¼1
wix
2
i 
Xn
i¼1
wixi
 !2
ð30Þ
with the weight defined as wi ¼
τiXn
i¼1
τj
[3]. Eq. (29) has the following important remarks. In
fact, LPðβ
!
, xnþ1Þ considers individual-level ethics by including LIðβ
!
, xnþ1Þ ¼ ðxnþ1  θγÞ
2 in the
numerator. By including ðxnþ1  μnÞ
2 in the denominator, where μn ¼
Xn
i¼1
wixi, the
population-level loss function reduces a loss by allocating the next patient further away from
the weighted average of previously allocated doses (i.e., devised from information gain). In
long run, LPðβ
!
, xnþ1Þ is devised from a compromise between individual- and population-level
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ethics, but the compromising process is rather too slow to be implemented in a small-sample
Phase I clinical trial [3].
4.5. Loss function for compromising the two perspectives
Kim and Gillen proposed to accelerate the compromising process by modifying LPðβ
!
, xnþ1Þ of
Eq. (29) as follows
LB,λðβ
!
, xnþ1Þ ¼
anðλÞ τnþ1ðxnþ1  θγÞ
2 þ s
ð0Þ
n ðθγ  μnÞ
2 þ σ2n
h i
s
ð0Þ
n s
ð2Þ
n  s
ð1Þ
n
h i
þ s
ð0Þ
n τnþ1 ðxnþ1  μnÞ
2 þ σ2n
h i , ð31Þ
where
anðλÞ ¼ 1þ
n
N
 λ 1þ
Xn
i¼1
yi
Nγ
 
ð32Þ
is an accelerating factor [3]. It has two implications. First, the compromising process is acceler-
ated toward the individual-level ethics as the trial proceeds (i.e., n increases). Second, the
compromising process toward the individual-level ethics is accelerated at a faster rate when
an adverse event is observed (i.e.,
Xn
i¼1
yi increases). The tuning parameter λ controls the rate
of acceleration. It imposes more emphasis on population-level ethics as λ ! 0 and more
emphasis on individual-level ethics as λ ! ∞. The choice of λ shall depend on the severity
level of an adverse event.
4.6. Simulation
To study the operating characteristics of LB,λ with respect to λ, we assume the logistic model
with β0 = 3 and β1 = .8 as a true dose-response relationship as shown in Figure 5 in the left
panel. The target risk level is fixed at γ = .2, so the true MTD is given by θ.2 = 2.02 in the
logarithmic scale. We consider three different priors based on the conditional mean priors
given in Eq. (22). For simplicity, we set a1 = 1, b1 = 3, a0 = 3 and b0 = 1 for all three priors.
Then, we let x1 ¼ 4 and x0 ¼ 4 for Prior 1; x1 ¼ 0 and x0 ¼ 8 for Prior 2; and x1 ¼ 4 and
x0 ¼ 12 for Prior 3. Figure 5 in the right panel shows an approximated f(θ.2) for each prior.
Prior 1 significantly underestimates the true θ
:2 ¼ 2:02 with prior mean Eðθ:2Þ ¼ 1:70, Prior 3
overestimates the truth with Eðθ
:2Þ ¼ 5:38, and Prior 2 has a prior estimate relatively close to
the truth with Eðθ
:2Þ ¼ 1:40.
Let N = 20 be a fixed sample size. Let Yi = 1 denote an adverse event observed from the ith
patient (Yi = 0 otherwise), so
XN
i¼1
Yi denotes the total number of adverse events observed at
the end of a trial. The sum
Xn
i¼1
Yi is random from a trial to another trial, and we want
Xn
i¼1
Yi
to behave like Binomialð20; :2Þ which is the case when we treat N = 20 to the true MTD θ.2.
Figure 6 shows three simulated trials under the loss function LB,λ with λ = 0,1,5. When λ = 0,
Bayesian Model Averaging and Compromising in Dose-Response Studies
http://dx.doi.org/10.5772/intechopen.68786
179
the up-and-down scheme has a high degree of fluctuation in order to maximize information
about θ.2. When λ = 1, the up-and-down scheme is stabilized after the first few adverse events,
and the stabilization occurs quickly when λ = 5 to treat trial participants near an estimated θ.2.
Let θ^
:2 ¼ Eðθ:2jy
!
NÞ, the posterior estimate of θ.2 at the end of a trial, so piθ^:2
implies the true
probability of an adverse event at the estimated MTD. We focus on the following criteria: (i)
Eðpi
θ^:2
Þwhich we desire to be close to γ ¼ :2 for future patients, (ii) Vðpi
θ^:2
Þwhich we desire to
be as low as possible for future patients, (iii) E½ðpi
θ^:2
 :2Þ2 which we desire to be as low as
possible for future patients, (iv) Eð
X20
i¼1
YiÞ which we desire to be close to Nγ ¼ 4 for trial
participants and (v) Pð3 ≤
X20
i¼1
Yi ≤ 5Þ which we desire to be close to one for trial participants.
True Dose−Response Curve
Dose (Logarithmic Scale)
P
ro
b
a
b
ili
ty
−4 0 4 82.02
0
.0
0
.2
0
.4
0
.6
0
.8
1
.0
Approximated Prior Distributions of MTD
θ0.2
−5 0 5 10
0
.0
0
0
.0
5
0
.1
0
0
.1
5
0
.2
0
0
.2
5
Prior 1
Prior 2
Prior 3
True MTD
Figure 5. The true dose-response relationship pix ¼ e
β0þβ1x
1þeβ0þβ1 x
with β0 = 3 and β1 = .8 (where x is the dose in the logarithmic
scale) in the simulation (left panel) and the three prior distributions of θ.2 approximated by kernel density (right panel).
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Figure 6. Three simulated trials using the loss function LB,λ with λ ¼ 0 (left), λ ¼ 1 (middle) and λ ¼ 5 (right) with a
sample of size N = 20 and assumed parameter values β0 ¼ 3, β1 ¼ 8 and θ:2 ¼ 2:02.
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Table 1 summarizes simulation results of 10,000 replicates for each prior. For all three priors,
we observe similar tendencies. First, Eðpi
θ^ :2
Þ gets closer to θ = .2 as λ increases. Second,
Vðpi
θ^ :2
Þ decreases as λ decreases to zero. The average square distance between pi
θ^:2
and
γ ¼ :2 measures a balance between jEðpi
θ^:2
Þ  :2 j and Vðpi
θ^ :2
Þ, and the superiority depends
on priors. Lastly, as λ ! 0, we have larger Pð3 ≤
X20
i¼1
Yi ≤ 5Þ and more robust Eð
X20
i¼1
YiÞ to
prior elicitation.
In summary, when we emphasize more on population-level ethics, we have a smaller variance
in the estimation for future patients (with a greater absolute bias, potentially due to Jensen’s
Inequality), and the distribution of
X
n
i¼1
Yi becomes more robust to prior elicitations. When we
emphasize more on individual-level ethics, we have a larger variance in the estimation, and the
distribution of
X
n
i¼1
Yi becomes more sensitive to prior elicitations.
5. Consensus prior
In Bayesian inference, researchers are able to utilize information, which is independent of
observed data. It allows researchers to incorporate any form of information, such as one’s experi-
ence and existing literature, which may be particularly useful in a small-sample study. On the
Prior λ Eðpi
θ^ :2
Þ Vðpi
θ^ :2
Þ E½ðpi
θ^ :2
 :2Þ2 Eð
X20
i¼1
Y iÞ Pð3 ≤
X20
i¼1
Y i ≤ 5Þ
1 0 0.0964 0.0019 0.0126 2.4353 0.4318
.5 0.1034 0.0024 0.0118 2.0997 0.2298
1 0.1082 0.0028 0.0113 1.8969 0.1714
2 0.1100 0.0031 0.0112 1.6929 0.1211
5 0.1157 0.0035 0.0106 1.3128 0.0596
2 0 0.1665 0.0054 0.0065 4.1217 0.9889
.5 0.1705 0.0056 0.0065 3.9598 0.9877
1 0.1727 0.0060 0.0068 3.9025 0.9670
2 0.1751 0.0066 0.0072 3.8707 0.9291
5 0.1763 0.0067 0.0073 3.8442 0.9068
3 0 0.2743 0.0048 0.0103 6.1875 0.1600
.5 0.2673 0.0048 0.0093 6.3954 0.1430
1 0.2606 0.0046 0.0083 6.6194 0.1165
2 0.2562 0.0045 0.0077 6.8035 0.1020
5 0.2499 0.0044 0.0068 7.0274 0.0760
Table 1. Simulation results of 10,000 replicates for λ = 0, .5, 1, 2, 5 and each prior.
Bayesian Model Averaging and Compromising in Dose-Response Studies
http://dx.doi.org/10.5772/intechopen.68786
181
other hand, we concern subjectivity and prior sensitivity in sparse data. Furthermore, it is possible
to have disagreement among multiple researchers’ prior elicitations about a parameter θ.
Suppose there are K researchers with their own prior density functions, say f ðθjQkÞ for
k ¼ 1;…, K, and they have the same likelihood function f ðy
!
jθÞ. Each prior elicitation leads to
a unique Bayes estimator
θ^ k
¼ Eðθjy
!
, QkÞ ¼
ð
θ f ðθjy
!
, QkÞ dθ , ð33Þ
where f ðθjy
!
, QkÞ ∝ f ðy
!
jθÞ f ðθjQkÞ is the posterior density function of θ given data y
!
and the
kth prior elicitation Qk. For posterior estimation, one reasonable approach to compromise is a
weighted average
XK
k¼1
wkθ^k, where wk > 0 for k = 1,…,K and
XK
k¼1
wk ¼ 1. In this section, we
discuss two different weighting methods. The first method is to fix wk before observing data
(referred to as prior weighting scheme). The second method is to determine wkðy
!
Þ after
observing data y
!
so that wkðy
!
Þ increases when the kth prior elicitation Qk is better supported
by the observed data y
!
(referred to as posterior weighting scheme) [5].
For a prior weighting scheme, we denote wk ¼ PðQkÞ which quantifies the credibility of the k
th
prior elicitation. For a posterior weighting scheme, we consider
wkðy
! Þ ¼ PðQkjy
!
Þ ¼
f ðy
!
jQkÞPðQkÞXK
j¼1
f ðy
!
jQjÞ PðQjÞ
¼
wk f ðy
!
jQkÞXK
j¼1
wj f ðy
!
jQjÞ
, ð34Þ
where f ðy
!
jQkÞ ¼
ð
f ðy
!
jθÞ f ðθjQkÞ dθ is the marginal likelihood from the k
th prior elicitation.
This formulation is similar to the BMA method discussed in Section 3. It can be shown thatXK
k¼1
wkðy
!
Þ θ^k is the Bayes estimator (the posterior mean of θ) when a consensus prior
f ðθÞ ¼
XK
k¼1
wk f ðθjQkÞ is used with wk ¼ PðQkÞ [5].
Samaniego discussed self-consistency when compromised inference is used through the prior
weighting scheme
XK
k¼1
wkθ^k [4]. Let θ denote a parameter of interest and
EðθÞ ¼
ð
θ f ðθÞ dθ ¼ θ ð35Þ
be the prior expectation, the mean of the prior density function f ðθÞ. Let ~θ denote a sufficient
statistic, which serves as an unbiased estimator for θ. When we satisfy Eðθj~θ ¼ θÞ ¼ θ, it is
called self-consistency [4].
Self-consistency can be achieved under simple models. For example, let Y
!
¼ ðY1,…, YnÞ be a
random sample, where Yi  BernoulliðθÞ, and assume θ  Betaða, bÞ for prior. It can be shown
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that the maximum likelihood estimator ~θ ¼ 1n
Xn
i¼1
Yi is a sufficient statistic and an unbiased
estimator for θ. The posterior mean is a weighted average between θ* and ~θ as follows
Eðθj~θ ¼ θÞ ¼ cθ þ ð1 cÞ ~θ , ð36Þ
where c ¼ aþbaþbþn. If we observe
~θ ¼ θ, we can achieve the self-consistency because
Eðθjθ^ ¼ θÞ ¼ θ. In words, when prior estimate and maximum likelihood estimate are iden-
tical, the posterior estimate must be consistent with the prior estimate and the maximum
likelihood estimate. The self-consistency can be also achieved in the prior weighting scheme
under certain conditions as illustrated in the following example.
5.1. Binomial experiment
Let Yi  BernoulliðpiÞ for i ¼ 1;…, n and assume Y1,…, Yn are independent. Suppose the k
th
researcher specifies the prior distribution pijQk  Betaðak, bkÞ for k ¼ 1;…, K. For the prior
weighting scheme, let wk ¼ PðQkÞ, the prior probability for the k
th prior elicitation (fixed before
observing data). Since EðpijQkÞ ¼
ak
akþbk
and the expectation E () is a linear operator, the average
of “consensus prior” is
EðpiÞ ¼
ð1
0
pi f ðpiÞ dpi ¼
ð1
0
pi
XK
k¼1
f ðpijQkÞ PðQkÞ

dpi ¼
XK
k¼1
wk
ð1
0
pi f ðpijQkÞ dpi

¼
XK
k¼1
wk EðpijQkÞ :
ð37Þ
Let EðpiÞ ¼ pi and suppose the K researchers observed the consistent result ~pi ¼ 1n
Xn
i¼1
Yi ¼ pi
.
The individual-specific Bayes estimator is as follows
p^ik ¼ Eðpij~pi ¼ pi
, QkÞ ¼ ck EðpijQkÞ þ ð1 ckÞ pi
 , ð38Þ
for the kth researcher, where ck ¼ akþbkakþbkþn. The compromised Bayes estimator is as follows
Eðpij~pi ¼ piÞ ¼
XK
k¼1
wk p^ik ¼
XK
k¼1
wk ck EðpijQkÞ þ ð1 ckÞpi
½  : ð39Þ
If we allow individual-specific prior elicitation ak and bk with the restriction ak + bk = m for all K
researchers (i.e., the same strength of prior elicitation), the value ck ¼ mmþn is constant over all
researcher. By letting the constant ck = c,
Eðpij~pi ¼ piÞ ¼ c
XK
k¼1
wk EðpijQkÞ
 !
þ ð1 cÞpi
XK
k¼1
wk
 !
¼ c EðpiÞ þ ð1 cÞpi ¼ pi , ð40Þ
so the self-consistency is satisfied.
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For the posterior weighting scheme given data y
!
¼ ðy1,…, ynÞ, the marginal likelihood from
the kth prior elicitation is as follows
f ðy
! jQkÞ ¼
ð1
0
f ðy
!
jpiÞ f ðpijQkÞ dpi ¼
Γðak þ bkÞ
ΓðakÞΓðbkÞ
Γðak þ sÞΓðbk þ n sÞ
Γðak þ bk þ nÞ
, ð41Þ
where s ¼
Xn
i¼1
yi is an observed sufficient statistic. Then, the posterior weighting scheme
becomes
XK
k¼1
wkðy
!
Þ p^ik with
wkðy
!
Þ ¼
wk f ðy
!
jQkÞXK
j¼1
wj f ðy
!
jQjÞ
,
p^ik ¼
ak þ s
ak þ bk þ n
:
ð42Þ
If we desire an equal strength from each researcher’s prior elicitation, we may fix ak þ bk ¼ m
and wk ¼ 1K. In the posterior weighting scheme, it is difficult to achieve the self-consistency.
Whether self-consistency is satisfied, the practical concern is the quality of estimation such as
bias, variance and mean square error. Assuming K = 2 researchers have disagreeing prior
knowledge and a sample of size n = 10, let us consider three cases. Suppose two researchers
express relatively mild disagreement as ða1, b1Þ ¼ ð1; 3Þ and ða2, b2Þ ¼ ð3; 1Þ in Case 1, relatively
strong disagreement as ða1, b1Þ ¼ ð2; 6Þ and ða2, b2Þ ¼ ð6; 2Þ in Case 2, and even stronger dis-
agreement as ða1, b1Þ ¼ ð3; 9Þ and ða2, b2Þ ¼ ð9; 3Þ in Case 3. For each case, Figure 7 provides the
relative bias, variance and mean square error (MSE) for comparing the posterior weighting
scheme
X3
k¼1
wkðy
!
Þ p^ik to the prior weighting scheme
X3
k¼1
wk p^ik. When a relative MSE is
smaller than one, it implies a smaller MSE for the posterior weighting scheme. As the true
value of pi is well between the two prior guesses EðpijQ1Þ ¼ :25 and EðpijQ2Þ ¼ :75, the poste-
rior weighting scheme shows a greater MSE due to greater variance. When the true value of pi
deviates away from either prior guess, the posterior weighting schemes show a smaller MSE
due to smaller bias. The tendency is stronger when the two disagreeing prior elicitations are
stronger (i.e., stronger prior disagreement). The bottom line is a clear bias-variance tradeoff
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Figure 7. Comparing prior and posterior weighting schemes for different degrees of disagreements.
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when we compare the two weighting schemes.
X3
k¼1
wkðy
!
Þ p^ik is able to reduce bias when there
is strong discrepancy between “consensus prior” and data, but it has larger variance thanX3
k¼1
wk p^ik because wkðy
!
Þ depends on random data.
5.2. Applications to Phase I trials under logistic regression model
In this section, we apply the prior weighting scheme and the posterior weighting scheme to
Phase I clinical trials under the logistic regression model. We consider the three priors consid-
ered in Section 4.6. We denote Prior 1, 2 and 3 by Q1, Q2 and Q3, respectively. The three priors
had the same hyper-parameters a1;k ¼ 1, b1;k ¼ 3, a0;k ¼ 3, b0;k ¼ 1, but they were different by
x1;k ¼ 4; 0; 4 and x0,k ¼ 4; 8; 12 for k ¼ 1; 2; 3, respectively. By the use of the conditional mean
prior in Eq. (22), the prior density function of β
!
for prior Qk is given by
f ðβ
!
jQkÞ ∝ ðx0;k  x1;kÞ
Y0
i¼1
eβ0þβ1xi
1þ eβ0þβ1xi
 ai,k 1
1þ eβ0þβ1xi
 bi,k
: ð43Þ
The prior means were Eðθ:2jQ1Þ ¼ 1:70, Eðθ:2jQ2Þ ¼ 1:40 and Eðθ:2jQ3Þ ¼ 5:38 for Priors 1, 2
and 3, respectively.
For simulation study, we consider three simulation scenarios with sample size N = 20. In
Scenario 1, we assume β0 = 5 and β1 = .6, so the true MTD is θ:2 ¼ 6:02, which deviates
significantly from all of the three prior means. In Scenario 2, we assume β0 = 3 and β1 = .8 as
in Section 4.6, so θ:2 ¼ 2:02 is well surrounded by the three prior means. In Scenario 3, we
assume β0 = 1 and β1 = 1.2, so θ:2 ¼ :32 is close to the most conservative prior mean
Eðθ:2jQ1Þ ¼ 1:70. We consider the loss function LIðβ
!
, xnþ1Þ ¼ ðxnþ1  θ:2Þ
2 discussed in Sec-
tion 4.4, which focuses on individual-level ethics. We use the uniform prior probabilities
wk ¼ PðQkÞ ¼ 1=3 for k ¼ 1; 2; 3 for implementing both prior and posterior weighting scheme.
Table 2 provides the simulation results of 10,000 replicates for each scenario under the prior
weighting scheme and under the posterior weighting scheme. Since the posterior weighting
scheme adaptively updates wkðy
!
Þ based on empirical evidence, it can reduce bias, but it has
greater variance in the estimation of θ2. As a consequence, when the true MTD was close to one
extreme prior estimate (Scenarios 1 and 3), the use of the posterior weighting scheme yields a
smaller E ðpi
θ^ :2
 :2Þ2
h i
, Eð
X20
i¼1
YiÞ closer to Nγ ¼ 4, and Pð3 ≤
X20
i¼1
Yi ≤ 5Þ closer to one when
compared to the use of the prior weighting scheme. In Scenario 3, the average number of adverse
events was 4.6 for the posterior weighting scheme, but it was as high as 7.1 in the prior weighting
scheme. On the other hand, when the true MTD was well surrounded by the three prior
estimates (Scenario 2), the use of the prior weighting scheme yielded more plausible results.
The simulation results are analogous to the simpler model in Section 5.1. When the true
parameter is not well surrounded by prior guesses, the posterior weighting scheme is prefer-
able with respect to mean square error due to smaller bias. When the true parameter is well
surrounded by prior guesses, the prior weighting scheme is beneficial with respect to mean
square error due to smaller variance.
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As a final comment, we shall be careful about the strength of individual prior elicitations when
we implement the posterior weighting scheme in Phase I clinical trials. The strength of indi-
vidual prior elicitations depends on (i) the hyper-parameters ai,k and bi,k, (ii) the prior weight
wk ¼ PðQkÞ as well as (iii) the distance between the two arbitrarily chosen doses x0;k  x1;k. It
can be seen through the expression
f ðβ
!
Þ ¼
XK
k¼1
f ðβ
!
jQkÞPðQkÞ ∝
XK
k¼1
wk ðx0;k  x1;kÞ
Y0
i¼1
eβ0þβ1xi
1þ eβ0þβ1xi
 ai,k 1
1þ eβ0þβ1xi
 bi,k
: ð44Þ
When researchers determine consensus prior elicitations before initiating a trial, the multiplicative
termwk ðx0;k  x1;kÞ shall be carefully considered togetherwith thehyper-parameters ai,k and bi,k [5].
6. Concluding remarks
In this chapter, we have discussed Bayesian inference with averaging, balancing, and compromis-
ing in sparse data. In the cancer risk assessment, we have observed that low-dose inference can be
very sensitive to an assumed parametric model (Section 3.1). In this case, the Bayesian model
averaging can be a useful method. It provides robustness by using multiple models and posterior
model probabilities to account for model uncertainty. In the application of Bayesian decision
theory to Phase I clinical trials, we have observed that the sequential sampling scheme heavily
depends on a loss function. A loss function, which is devised from individual-level ethics, focuses
on the benefit of trial participants, and a loss function, which is devised from population-level
ethics, focuses on the benefit of future patients. It is possible to balance between the two
conflicting perspectives, and we can adjust a focusing point by the tuning parameter (Sections
4.5 and 4.6). Finally, the use of a weighted posterior estimate can be a compromising method
when two or more researchers have prior disagreement. We have compared the prior and
posterior weighting schemes in a small-sample binomial problem (Section 5.1) and in a small-
sample Phase I clinical trial (Section 5.2). The prior weighting scheme (data-independent weights)
outperforms when prior estimates surround the truth, and the posterior weighting scheme (data-
dependent weights) outperforms when the truth is not well surrounded by prior estimates. One
method does not outperform the other method for all parameter values, so it is important to be
aware of their bias-variance tradeoff.
Scenario Method Eðpi
θ^ :2
Þ Vðpi
θ^ :2
Þ E½ðpi
θ^ :2
 :2Þ2 Eð
X20
i¼1
Y iÞ Pð3 ≤
X20
i¼1
Y i ≤ 5Þ
1 Prior weighting 0.0967 0.0014 0.0121 1.1090 0.0398
Posterior weighting 0.1853 0.0073 0.0075 2.7304 0.5900
2 Prior weighting 0.2018 0.0059 0.0059 3.8432 0.9042
Posterior weighting 0.2048 0.0110 0.0110 4.2848 0.8920
3 Prior weighting 0.2929 0.0071 0.0157 7.1090 0.0568
Posterior weighting 0.1951 0.0133 0.0133 4.6036 0.8646
Table 2. Simulation results of 10,000 replicates for the prior and posterior weighting schemes.
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